202 related articles for article (PubMed ID: 14762605)
1. [Acoustic analysis of prosody in females with Parkinson's disease: effect of L-dopa].
Azevedo LL; Cardoso F; Reis C
Arq Neuropsiquiatr; 2003 Dec; 61(4):995-8. PubMed ID: 14762605
[TBL] [Abstract][Full Text] [Related]
2. [Acoustic analysis of prosody in females with Parkinson's disease: comparison with normal controls].
Azevedo LL; Cardoso F; Reis C
Arq Neuropsiquiatr; 2003 Dec; 61(4):999-1003. PubMed ID: 14762606
[TBL] [Abstract][Full Text] [Related]
3. [Speech and voice disorders in Parkinson's disease].
Martnez-Sánchez F
Rev Neurol; 2010 Nov; 51(9):542-50. PubMed ID: 20979034
[TBL] [Abstract][Full Text] [Related]
4. Acoustic investigation of stress patterns in Parkinson's disease.
Tykalova T; Rusz J; Cmejla R; Ruzickova H; Ruzicka E
J Voice; 2014 Jan; 28(1):129.e1-129.e8. PubMed ID: 24094802
[TBL] [Abstract][Full Text] [Related]
5. [F0 characteristics in Parkinsonian speech: Contrast between the effect of hypodopaminergy due to Parkinson's disease and that of the therapeutic delivery of L-Dopa].
Ghio A; Robert D; Grigoli C; Mas M; Delooze C; Mercier C; Viallet F
Rev Laryngol Otol Rhinol (Bord); 2014; 135(2):63-70. PubMed ID: 26521344
[TBL] [Abstract][Full Text] [Related]
6. Phonatory characteristics of parkinsonian speech before and after morning medication: the ON and OFF states.
Goberman A; Coelho C; Robb M
J Commun Disord; 2002; 35(3):217-39. PubMed ID: 12064785
[TBL] [Abstract][Full Text] [Related]
7. Prosody and levodopa in Parkinson's disease.
Azevedo LL; Reis CA; Souza IS; Cardoso FE
Arq Neuropsiquiatr; 2013 Nov; 71(11):835-40. PubMed ID: 24394867
[TBL] [Abstract][Full Text] [Related]
8. Acoustic analysis of parkinsonian speech I: speech characteristics and L-Dopa therapy.
Goberman AM; Coelho C
NeuroRehabilitation; 2002; 17(3):237-46. PubMed ID: 12237505
[TBL] [Abstract][Full Text] [Related]
9. Quantitative acoustic measurements for characterization of speech and voice disorders in early untreated Parkinson's disease.
Rusz J; Cmejla R; Ruzickova H; Ruzicka E
J Acoust Soc Am; 2011 Jan; 129(1):350-67. PubMed ID: 21303016
[TBL] [Abstract][Full Text] [Related]
10. Effects of dopaminergic replacement therapy on motor speech disorders in Parkinson's disease: longitudinal follow-up study on previously untreated patients.
Rusz J; Tykalová T; Klempíř J; Čmejla R; Růžička E
J Neural Transm (Vienna); 2016 Apr; 123(4):379-87. PubMed ID: 26843071
[TBL] [Abstract][Full Text] [Related]
11. Acoustic analysis of speech intonation pattern of individuals with Autism Spectrum Disorders.
Olivati AG; Assumpção FB; Misquiatti AR
Codas; 2017 Apr; 29(2):e20160081. PubMed ID: 28403279
[TBL] [Abstract][Full Text] [Related]
12. Effect of speech therapy and pharmacological treatment in prosody of parkinsonians.
Azevedo LL; Souza IS; Oliveira PM; Cardoso F
Arq Neuropsiquiatr; 2015 Jan; 73(1):30-5. PubMed ID: 25608124
[TBL] [Abstract][Full Text] [Related]
13. Relationship Between Voice and Motor Disabilities of Parkinson's Disease.
Majdinasab F; Karkheiran S; Soltani M; Moradi N; Shahidi G
J Voice; 2016 Nov; 30(6):768.e17-768.e22. PubMed ID: 26725551
[TBL] [Abstract][Full Text] [Related]
14. Relationship between acoustic measures and speech naturalness ratings in Parkinson's disease: A within-speaker approach.
Klopfenstein M
Clin Linguist Phon; 2015; 29(12):938-54. PubMed ID: 26403503
[TBL] [Abstract][Full Text] [Related]
15. Relative fundamental frequency during vocal onset and offset in older speakers with and without Parkinson's disease.
Stepp CE
J Acoust Soc Am; 2013 Mar; 133(3):1637-43. PubMed ID: 23464033
[TBL] [Abstract][Full Text] [Related]
16. Effect of dopaminergic medication on speech dysfluency in Parkinson's disease: a longitudinal study.
Tykalová T; Rusz J; Čmejla R; Klempíř J; Růžičková H; Roth J; Růžička E
J Neural Transm (Vienna); 2015 Aug; 122(8):1135-42. PubMed ID: 25583417
[TBL] [Abstract][Full Text] [Related]
17. Fundamental Frequency and Intensity Effects on Cepstral Measures in Vowels from Connected Speech of Speakers with Voice Disorders.
Sampaio MC; Bohlender JE; Brockmann-Bauser M
J Voice; 2021 May; 35(3):422-431. PubMed ID: 31883852
[TBL] [Abstract][Full Text] [Related]
18. Residual signal auto-correlation to evaluate speech in Parkinson's disease patients.
Pereira JC; Schelp AO; Montagnoli AN; Gatto AR; Spadotto AA; de Carvalho LR
Arq Neuropsiquiatr; 2006 Dec; 64(4):912-5. PubMed ID: 17220994
[TBL] [Abstract][Full Text] [Related]
19. Progression of dysprosody in Parkinson's disease over time--a longitudinal study.
Skodda S; Rinsche H; Schlegel U
Mov Disord; 2009 Apr; 24(5):716-22. PubMed ID: 19117364
[TBL] [Abstract][Full Text] [Related]
20. Levodopa may modulate specific speech impairment in Parkinson's disease: an fMRI study.
Mračková M; Mareček R; Mekyska J; Košťálová M; Rektorová I
J Neural Transm (Vienna); 2024 Feb; 131(2):181-187. PubMed ID: 37943390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
